Is Genpact Limited (G) a Good Stock to Buy?

Now, key money managers have been driving this bullishness. Citadel Investment Group, led by Ken Griffin, established the most outsized position in Genpact Limited (NYSE:G). Citadel Investment Group had $17.8 million invested in the company at the end of the quarter. Greg Poole’s Echo Street Capital Management also made a $17 million investment in the stock during the quarter. The following funds were also among the new G investors: James Parsons’ Junto Capital Management, Matthew Tewksbury’s Stevens Capital Management, and David Rodriguez-Fraile’s BlueMar Capital Management.

Let’s check out hedge fund activity in other stocks similar to Genpact Limited (NYSE:G). These stocks are Polaris Industries Inc. (NYSE:PII), Dun & Bradstreet Corp (NYSE:DNB), athenahealth, Inc (NASDAQ:ATHN), and Core Laboratories N.V. (NYSE:CLB). This group of stocks’ market caps are similar to Genpact Limited’s market cap.

As you can see these stocks had an average of 18 funds with bullish positions and the average amount invested in these stocks was $153 million. That figure was $428 million in Genpact’s case. Core Laboratories N.V. (NYSE:CLB) is the most popular stock in this table. On the other hand Polaris Industries Inc. (NYSE:PII) is the least popular one with only 12 bullish hedge fund positions. Genpact Limited (NYSE:G) is not the most popular stock in this group but hedge fund interest is still above average. This is a slightly positive signal but we’d rather spend our time researching stocks that hedge funds are piling on. In this regard Core Laboratories N.V. (NYSE:CLB) might be a better candidate to consider taking a long position in.

Disclosure: none